MedTrace Logo

Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)

NCT01704794 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2013-04-04

No results posted yet for this study

Summary

The purpose of this study is to determine the antioxidant effect of prolonged use of sorghum bicolor (jobelyn) to increase the level of plasma superoxide dismutase and glutathione reductase in patients with sickle cell disease and to determine if there is any improvement in the quality of life of the patients.

Conditions

  • Other Sickle-cell Disorders With Crisis, Unspecified

Interventions

DIETARY_SUPPLEMENT

Folic Acid + Paludrine + Jobelyn (500mg)

Combination of routine drugs + Jobelyn

DRUG

Folic Acid + Paludrine + Jobelyn (250mg)

Standard routine drugs for treatment of SCD with 250mg Jobelyn

DIETARY_SUPPLEMENT

Folic Acid + Paludrine + Jobelyn (2mg)

Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)

Sponsors & Collaborators

  • Lagos State University

    lead OTHER

Principal Investigators

  • A O Dosunmu, M.D. · Lagos State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-04-30
Completion
2014-09-30

Countries

  • Nigeria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01704794 on ClinicalTrials.gov